TY - JOUR
T1 - Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure
AU - Feio-Azevedo, Rita
AU - Boesch, Markus
AU - Radenkovic, Silvia
AU - Van Melkebeke, Lukas
AU - Smets, Lena
AU - Wallays, Marie
AU - Boeckx, Bram
AU - Philips, Gino
AU - Prata De Oliveira, Janaíne
AU - Ghorbani, Mohammad
AU - Laleman, Wim
AU - Meersseman, Philippe
AU - Wilmer, Alexander
AU - Cassiman, David
AU - Van Malenstein, Hannah
AU - Triantafyllou, Evangelos
AU - Sánchez, Cristina
AU - Aguilar, Ferran
AU - Nevens, Frederik
AU - Verbeek, Jef
AU - Moreau, Richard
AU - Arroyo, Vicente
AU - Denadai Souza, Alexandre
AU - Clària, Joan
AU - Lambrechts, Diether
AU - Ghesquière, Bart
AU - Korf, Hannelie
AU - Van Der Merwe, Schalk
N1 - Publisher Copyright:
Copyright © 2024 The Author(s).
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Background and Aims: Acute-on-chronic liver failure (ACLF) is a complication of cirrhosis characterized by multiple organ failure and high short-term mortality. The pathophysiology of ACLF involves elevated systemic inflammation leading to organ failure, along with immune dysfunction that heightens susceptibility to bacterial infections. However, it is unclear how these aspects are associated with recovery and nonrecovery in ACLF. Approach and Results: Here, we mapped the single-cell transcriptome of circulating immune cells from patients with ACLF and acute decompensated (AD) cirrhosis and healthy individuals. We further interrogate how these findings, as well as immunometabolic and functional profiles, associate with ACLF-recovery (ACLF-R) or nonrecovery (ACLF-NR). Our analysis unveiled 2 distinct states of classical monocytes (cMons). Hereto, ACLF-R cMons were characterized by transcripts associated with immune and stress tolerance, including anti-inflammatory genes such as RETN and LGALS1. Additional metabolomic and functional validation experiments implicated an elevated oxidative phosphorylation metabolic program as well as an impaired ACLF-R cMon functionality. Interestingly, we observed a common stress-induced tolerant state, oxidative phosphorylation program, and blunted activation among lymphoid populations in patients with ACLF-R. Conversely, ACLF-NR cMon featured elevated expression of inflammatory and stress response genes such as VIM, LGALS2, and TREM1, along with blunted metabolic activity and increased functionality. Conclusions: This study identifies distinct immunometabolic cellular states that contribute to disease outcomes in patients with ACLF. Our findings provide valuable insights into the pathogenesis of ACLF, shedding light on factors driving either recovery or nonrecovery phenotypes, which may be harnessed as potential therapeutic targets in the future.
AB - Background and Aims: Acute-on-chronic liver failure (ACLF) is a complication of cirrhosis characterized by multiple organ failure and high short-term mortality. The pathophysiology of ACLF involves elevated systemic inflammation leading to organ failure, along with immune dysfunction that heightens susceptibility to bacterial infections. However, it is unclear how these aspects are associated with recovery and nonrecovery in ACLF. Approach and Results: Here, we mapped the single-cell transcriptome of circulating immune cells from patients with ACLF and acute decompensated (AD) cirrhosis and healthy individuals. We further interrogate how these findings, as well as immunometabolic and functional profiles, associate with ACLF-recovery (ACLF-R) or nonrecovery (ACLF-NR). Our analysis unveiled 2 distinct states of classical monocytes (cMons). Hereto, ACLF-R cMons were characterized by transcripts associated with immune and stress tolerance, including anti-inflammatory genes such as RETN and LGALS1. Additional metabolomic and functional validation experiments implicated an elevated oxidative phosphorylation metabolic program as well as an impaired ACLF-R cMon functionality. Interestingly, we observed a common stress-induced tolerant state, oxidative phosphorylation program, and blunted activation among lymphoid populations in patients with ACLF-R. Conversely, ACLF-NR cMon featured elevated expression of inflammatory and stress response genes such as VIM, LGALS2, and TREM1, along with blunted metabolic activity and increased functionality. Conclusions: This study identifies distinct immunometabolic cellular states that contribute to disease outcomes in patients with ACLF. Our findings provide valuable insights into the pathogenesis of ACLF, shedding light on factors driving either recovery or nonrecovery phenotypes, which may be harnessed as potential therapeutic targets in the future.
UR - http://www.scopus.com/inward/record.url?scp=85199293810&partnerID=8YFLogxK
U2 - 10.1097/HEP.0000000000000907
DO - 10.1097/HEP.0000000000000907
M3 - Article
C2 - 38761406
AN - SCOPUS:85199293810
SN - 0270-9139
VL - 81
SP - 509
EP - 522
JO - Hepatology
JF - Hepatology
IS - 2
ER -